london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Pattern of Vogt-Koyanagi-Harada disease in children

Poster Details

First Author: M.Khairallah TUNISIA

Co Author(s):    S. Khochtali   F. Gatfaoui   M. Chaabane   A. Ben Abdallah   S. Attia   R. Messaoud   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To report clinical findings and visual outcome of Vogt-Koyanagi-Harada (VKH) disease in childhood (patients < 16 years old).

Setting:

Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia .

Methods:

Retrospective study including 5 children (10 eyes) with VKH disease. All patients underwent detailed ophthalmic examination, fluorescein angiography, and optical coherence tomography. Mean follow-up was 12 months (range, 6-24).

Results:

Mean age of our patients was 8 years (range, 6-12). Three patients (60%) were male and 2 patients (30%) were female. All patients were diagnosed at the chronic recurrent stage. Mean initial visual acuity was 20/63 (range, 20/800-20/25).Ophthalmic findings included anterior granulomatous uveitis (60%), band keratopathy (20%), posterior synechiae (40%), intraocular hypertension (20%), cataract (40%), sunset glow fundus (100%), and subretinal fibrosis (10%). Poliosis and vitiligo were recorded in 2 patients (40%). All patients were treated with oral corticosteroids and immunosuppressive therapy (cyclosporine=3, azathioprine=1 ,methotrexate=1). Three eyes (60%) underwent cataract surgery. Mean final visual acuity was 20/63(range, 20/200-20/25).

Conclusions:

VKH disease is an uncommon cause of uveitis in children. The disease is often recognized late in the course of the disease. The use of immunosuppressive therapy or biologic agents is necessary. Delay of diagnosis and treatment may lead to poor prognosis due to chronic recurrent inflammation and complications.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy